Janssen Biotech, Inc. clinical trials
Acquired by Johnson & Johnson, Oct 1999 · source ↗
The registry lists 13 studies whose lead sponsor is Janssen Biotech, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Before and after it joined Johnson & Johnson
- First submitted before Janssen Biotech, Inc. became part of Johnson & Johnson
- 0
- First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- 13
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Janssen Biotech, Inc.13 studies
Something wrong with this grouping? Tell us on the Johnson & Johnson page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All Johnson & Johnson studies →
- An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisActive, not recruitingNCT02808780
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel DiseaseActive, not recruitingNCT00606346
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific AntigenCompletedNCT01314118Phase 2
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- Ustekinumab Safety and Surveillance Program Using the Ingenix NHI DatabaseCompletedNCT01081730
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- Golimumab Safety and Surveillance Program Using the Ingenix NHI DatabaseCompletedNCT01081717
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and PsoriasisCompletedNCT00658827
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaApproved for marketingNCT01833039
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)TerminatedNCT01962974Phase 3
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque PsoriasisCompletedNCT01550744Phase 3
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of RecurrenceTerminatedNCT01190839Phase 3
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque PsoriasisCompletedNCT01555606
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)CompletedNCT01004432Phase 3
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson
- The Crohn's Therapy, Resource, Evaluation, and Assessment Tool RegistryCompletedNCT00553176
Sponsor listed in the registry: Janssen Biotech, Inc. · First submitted after Janssen Biotech, Inc. became part of Johnson & Johnson